Literature DB >> 32172529

Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.

Hiroaki Matsumoto1, Koji Shiraishi1, Haruhito Azuma2, Keiji Inoue3, Hirotsugu Uemura4, Masatoshi Eto5, Chikara Ohyama6, Osamu Ogawa7, Eiji Kikuchi8, Hiroshi Kitamura9, Nobuo Shinohara10, Satoru Takahashi11, Toyonori Tsuzuki12, Masayuki Nakagawa13, Yoshifumi Narumi14, Hiroyuki Nishiyama15, Tomonori Habuchi16, Shiro Hinotsu17, Yasuhisa Fujii18, Kiyohide Fujimoto19, Hiroyuki Fujimoto20, Takashi Mizowaki21, Hideyasu Matsuyama1.   

Abstract

The Clinical Practice Guidelines for Bladder Cancer edited by the Japanese Urological Association were first published in 2009 and a revised edition was released in 2015. Four years has passed since the 2015 edition, and the clinical practice environment surrounding bladder cancer has drastically changed during that time. The main changes include: (i) insurance coverage of a new diagnostic method for non-muscle-invasive bladder cancer; (ii) insurance coverage of an immune checkpoint inhibitor in advanced and metastatic bladder cancer; and (iii) advances in robot-assisted radical cystectomy as a minimally invasive treatment for muscle-invasive bladder cancer. A paradigm shift in bladder cancer diagnosis and treatment is occurring day by day. Therefore, in this 2019 edition, while dealing with the above changes, we carefully selected clinical questions with clear evidence and included other clinically important points in the general statement. We also added a new chapter on rare cancers of the urinary tract. As a new method for the evaluation of study evidence level, we introduce "The Grading of Recommendations Assessment, Development and Evaluation" system modified to Japanese by the Medical Information Network Distribution Service.
© 2020 The Japanese Urological Association.

Entities:  

Keywords:  Japanese Urological Association; bladder cancer; clinical practice guidelines; evidence-based medicine; position statement

Mesh:

Year:  2020        PMID: 32172529     DOI: 10.1111/iju.14210

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

1.  UroVysion® predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study.

Authors:  Hidehiro Iwata; Naoto Sassa; Masashi Kato; Yota Murase; Shuko Seko; Hideji Kawanishi; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

Review 2.  Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers.

Authors:  Zitong Yang; Qinchen Li; Xiangyi Zheng; Liping Xie
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.

Authors:  Makito Miyake; Nobutaka Nishimura; Yasushi Nakai; Tomomi Fujii; Takuya Owari; Shunta Hori; Yosuke Morizawa; Daisuke Gotoh; Satoshi Anai; Kazumasa Torimoto; Nobumichi Tanaka; Yoshihiko Hirao; Kiyohide Fujimoto
Journal:  Diagnostics (Basel)       Date:  2021-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.